Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

[1] Mirnejad R(2018)Clofazimine: a useful antibiotic for drug-resistant tuberculosis Biomed Pharmacother Biomed Pharmacothera 105 1353-1359

[2] Asadi A(2018)Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis Lancet (London, England) 392 821-834

[3] Khoshnood S(2016)Bdq in the treatment of multidrug- and extensively drug-resistant tuberculosis Eur Respir J 47 564-574

[4] Ahmad N(2020)Long-term impact of the adoption of Bdq-containing regimens on the burden of drug-resistant tuberculosis in China BMC Infect Dis 20 113-1801

[5] Ahuja SD(2015)WHO's new end TB strategy Lancet (London, England) 385 1799-454

[6] Akkerman OW(2012)Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis 16 447-142

[7] Pym AS(2018)Defining Bdq susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study EBioMedicine 28 136-706

[8] Diacon AH(2018)Effect of Bdq on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study Lancet Respir Med 6 699-470

[9] Tang SJ(2021)Interim effectiveness and safety comparison of Bdq-containing regimens for treatment of diabetic versus non-diabetic MDR/XDR-TB patients in China: a multicenter retrospective cohort study Infect Dis Ther 10 457-230

[10] Agnarson AM(2020)Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients Indian J Tuberc 67 222-1529

[1] Mirnejad R(2018)Clofazimine: a useful antibiotic for drug-resistant tuberculosis Biomed Pharmacother Biomed Pharmacothera 105 1353-1359

[2] Asadi A(2018)Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis Lancet (London, England) 392 821-834

[3] Khoshnood S(2016)Bdq in the treatment of multidrug- and extensively drug-resistant tuberculosis Eur Respir J 47 564-574

[4] Ahmad N(2020)Long-term impact of the adoption of Bdq-containing regimens on the burden of drug-resistant tuberculosis in China BMC Infect Dis 20 113-1801

[5] Ahuja SD(2015)WHO's new end TB strategy Lancet (London, England) 385 1799-454

[6] Akkerman OW(2012)Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis 16 447-142

[7] Pym AS(2018)Defining Bdq susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study EBioMedicine 28 136-706

[8] Diacon AH(2018)Effect of Bdq on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study Lancet Respir Med 6 699-470

[9] Tang SJ(2021)Interim effectiveness and safety comparison of Bdq-containing regimens for treatment of diabetic versus non-diabetic MDR/XDR-TB patients in China: a multicenter retrospective cohort study Infect Dis Ther 10 457-230

[10] Agnarson AM(2020)Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients Indian J Tuberc 67 222-1529